Search Engine - What we got wrong about GLP-1s

Episode Date: April 10, 2026

Search Engine is breaking its cowardly three-year silence on GLP-1s. We have been curious about them. We have been afraid of getting in trouble. We are no longer afraid. A conversation with Dr. Rachael Bedard about the many mistakes in how the media covered these drugs and what the research shows about their surprising effects.  Dr. Bedard’s story on the rise of Ozempic Support the show! To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

This episode of Search Engine is brought to you in part by Square. Square, the easy way for business owners to take payments, book appointments, manage staff, and keep everything running in one place. Whether you're selling lattes, cutting hair, detailing cars, or running a design studio, Square helps you run your business without running yourself into the ground. I like seeing Square in action at my local coffee shop. They use Square for payments, and it just makes everything feel effortless. Quick checkout, digital receipts, sometimes even loyalty points.

It really enhances the experience and, like, lets the team focus on serving great coffee, not fumbling with the register. Square works wherever your customers are. You can manage inventory, track sales, and access reports in real time. With Square, you get all the tools to run your business with none of the contracts or complexity. And why wait? Right now, you can get up to $200 off Square hardware at square.com slash go slash engine. That's SQ-U-A-R-E dot com slash geo-engine.

Run your business smarter, the Square gets started today. This episode of Search Engine is brought to you in part by Framer. Your marketing website sets the tone for your brand and is the one touchpoint every single one of your customers has. If you still struggle to make small changes and simple updates, you're leaving opportunity on the table. That's why so many companies, from early stage startups to Fortune 500s, are turning to Framer, the website builder that turns your dot com from a formality into a tool for growth, helping businesses build better websites faster. Framers is an enterprise solution, with premium hosting, enterprise-grade security,

and 99.99% uptime SLAs that gives the world's leading brands like perplexity, Miro, and Mix panel the confidence they need to build their websites and Framer. Learn how you can get more out of your dot com from a Framer specialist or get started building for free today at Framer.com slash search for 30% off a Framer.com slash search for 30% off. Framer.com slash search rules and restrictions may apply. Okay, so here's something. our show's motto.

No question too big, no question too small. But there's some questions that I have on this show of WIDD. I'll give you an example. GLP-1s. Surge Engine has barely acknowledged their existence, which is fine, except I read a lot about them, I think a lot about them, and in my private life, I talk a lot about them.

But when they canniballed into American culture, I had a lot of questions that I didn't want to ask in public. In 2022 and 2023, gLP ones were just, for me, too hot a topic. Going online felt like walking into a crazy shootout in an old Western saloon. Except instead of gunslingers, it was all fast-draw scolders.

There were scolders out there scolding celebrities for taking GLP-1s, but then they were getting scolded by other scolders for scolding celebrities. Some people got scolded because they were taking the drugs despite not being fat enough, scolded for wanting to lose 15 pounds. Rich people, of course, were getting scolded all over the place,

accused of ripping GLP-1s out of the hands of the people who actually needed them. It was scolding mayhem. Meanwhile, offline in real life, 20% of the people I knew just lost 15 to 40 pounds. They seemed happy, and I had questions. What did we really know about these drugs? Were they helping people the way they claimed to? What were the side effects? I had questions, but I hate getting scolded.

So I kept my mouth shut. Meanwhile, in 26, the scolders have moved on to other topics. Topics I'll cover in 2029. But today, we can finally get some answers on these fascinating drugs, which it turns out are much we're much we ever knew. So this week, we're going to talk to a doctor who's going to tell us the story of GLP1s from her perspective, which is a very unique one. Because she's a doctor to a particular patient population that we don't hear from much in the media. almost never, and who were very absent from the entire early discourse around these drugs. Can you say your name and what you do?

Sure. I'm Rachel Bedard. I'm a physician and I'm a writer. Am I contributing a writer to New York Times opinion? And as a doctor, I am an internist and my subspecialties are geriatrics and palliative care. But I've had this sort of unusual career where for six years I was a physician on Rikers Island. And I now work in a homeless clinic a couple days a week. Can you tell me about your work at that homeless clinic? Like where's the clinic? What's it like? What's your work like? So the clinic is, it's a safety net clinic run by the city.

The city is a network of these safety net clinics that are embedded in the public hospital system. And so my clinic is at Woodhull Hospital in Brooklyn. So the clinic's in the hospital, but it's an outpatient clinic, it's primary care. We serve people who are either unhoused or sort of in precarious housing situations. they were recently housed or they are staying on friends' couches or something like that. But the majority of the people that we take care of are living in shelter or people who are sleeping on the streets. So we do sort of all of their primary care. That population has a very high rate of comorbid mental health issues, very high rate of comorbid addiction issues,

but also is just very medically sick. So the majority of folks that I take care of have at least one chronic medical comorbidious. like high blood pressure, diabetes, or other diseases like that, for which they're taking daily medications. I have like a bunch of questions in a bunch of different directions. One is your work puts you, I think a lot of people who live in New York City, the weird thing about New York, maybe more than other places in America, is that it's both incredibly class stratified.

you have very elite, very wealthy people, and you've working people, and you're very poor people. But the people in those worlds don't always really run into each other besides maybe on the subway or literally on the street. You have this unusual life where you're moving between highly elite worlds, like the New York Times, and then working with populations that are so far removed from it. And I just wonder, the thing that I think so many people block out in their minds

in order to just live in a city, you've chosen to give yourself a life where you can't. I'm just wondering what that's like. Yeah, so, you know, one thing I'll say about New York is, although the rates of inequality here are astounding, there is, I think, actually more mixing in New York City than there is in a city like L.A., for example, where people are always in their cars, right? Like, you are sort of interacting on the streets and on the subways, et cetera, you know, and because of the density, people are just on top of each other much more.

So it doesn't feel, my life certainly feels extremely stratified for lots of reasons, but I think I like living here because it feels as though humanity is in continuity with itself in a way that in some other parts of the country or other very wealthy cities, you can be completely sort of cloistered off. That having been said, yes, my clinical work puts me in not just contact with, but I think just an extremely intimate relationship with people whose lives are. are really, really difficult in ways that my life has never been and gives me a different sort of level of insight into what it's like to live in those circumstances. Right. You get this very, very intimate view into lives that are very different from your own. Right. Like my patients, their experience of the weather

is really different than my experience of the weather because they are exposed to the elements in ways that I am not with fewer ways to protect themselves, ranging from like they come to the clinic and they don't have a coat and they don't have gloves. and it's really cold outside, or it's really hot outside, and they don't necessarily have a place to take cover from that, right? And so, like, that's a really different way to be in a body

in the same spaces than I'm in my body in, if that makes sense. It completely makes sense. How did you end up working at the homeless clinic? Well, I, so I had gone into medicine because I wanted to do sort of social medicine, like social justice work through medicine. And it wasn't totally obvious how to do that. And I sort of very luckily, by chance,

ended up in this job out of fellowship at Rikers, where my job was to take care of older people who were incarcerated in the New York City jail system. And I loved that job so much. What does it look like day-to-day to be a doctor at Rikers? Rikers is a wild place because it is, it's an island, as you know. I've been once, actually. Oh, have you?

Yeah, but you should describe it because I guess the median listener probably has not been. Yeah, so Rikers Island is an island off of Queens. It is connected to Queens via this long bridge. There's security at the front of the bridge, and on the other side, you can only drive on the island. You aren't allowed to walk on the island. It's sort of a fortress unto itself that the Department of Corrections for New York City runs. And it is a complex of multiple jails that are all on this island, a bunch of different buildings. The buildings house people sort of in difference of special populations.

There's one for women. There's one for people who are sicker. There are ones for specialized mental health units. And depending on the kind of medicine you practice, your day can look very different. So for the first few years that I worked there, I would basically print a list of everybody in the system who is older than 65. And I would go sort of try to find those people where they were and call them down to a clinic in that building. There's no freedom of movement in the New York City Jail system, which means that every time a guy, moves from one place to another, he has to be accompanied by an officer.

Like, somebody has to come pick him up and unlock a door and take him out and bring him to you. So things move very slowly. Like, it's like being in the airport all the time, right? Or the emergency room is an incredibly sort of congested system that requires a huge amount of excess human contact. It's hard to have real privacy during clinical encounters because you're not actually sort of behind a truly closed door ever for safety reasons. But you can imagine that there's, like, a tension there with being able to provide care

to people who are ambivalent about revealing themselves in that kind of environment, right? And so it is a clinical dynamic that's very much constrained by the security concerns of the system. And some of those security concerns are really well justified, and some aren't. One of the first patients I had with advanced cancer, I went to visit him while he was in the hospital, incarcerated. There was a corrections officer sitting outside his room. He had told me he really like Skittles, the patient. I brought Skittles.

I had to open my bag and show the officer what was in my bag before I was allowed in the room. And I was too sort of junior to know that I should play it cool

and I said I brought him Skittles and the guy said he's not allowed to have those and I said, why? And he said, well, skittles aren't on commissary so he's not allowed to have things that aren't on commissary.

That's like obviously not a real security concern, right? That's just a rule. Yeah. And that's not a law, you know, even though the guy's saying it to me is in a uniform.

And I was like, I'm going to give him the skittles. You know. And you can imagine that that's hard to do. And you have to have a fair amount. You have to really feel empowered by the folks who run the health care side of things to be able to use your judgment like that. And I was super lucky in who my bosses were.

I was there for COVID. That was really wild. It made me feel incredibly bonded to a bunch of my colleagues and my supervisors. And then I left at the beginning of 2022 quite burnt out. And a bunch of people who I worked with at Rikers, moved on to work at Woodhall. And it was like, you know, like in Mad Men when they like remake the first, you know what I mean? They like, they're like season three, we're doing a new one. That's like the same guys. That's what it was like. We'd like mad men up at Woodhall, which is a bunch

of people who I loved working with at Rikers, were super mission driven. And so that's how I ended up there. And so you're there now and it sounds like the thing that, I mean, there are many things in common, the people you're working with in common. But the other thing that sounds shared is that I think when a layman thinks about a doctor, it's a person you go to and they figure out what's wrong with you and they give you medicine. And your experience of medical care is that oftentimes the job is as much about the social structures around people as just like treating their bodies. Because the things that are happening to their bodies and the social structures they're in Meshden are so inseparable. Yes. Although I would say that's truly true for any practice environment, any patient population. Really?

It's just, yeah, it's just the challenges are really different. more visible, I think, with my patient population. But if you are paying out-of-pocket to see a concierge doctor, which in New York, there's, like, this incredible stratification and access to primary care. And one, at the high end, people are paying out-of-pocket to see concierge doctors, which means that they're paying some huge amount of money to have this person basically be on call to see them. And the dynamics of that relationship are totally determined by that payment model by that person's socioeconomic status, by their access to be able to get care from other kinds of specialists, by their ability to, like, you know, that doctor says maybe you need a massage

for this back pain and the person can pay for that massage, right? It's sort of impossible to separate the body from the social. And that's just particularly visible and the social sort of circumstances for my patients are just so particularly crushing and throwing up obstacles so they're of being able to take care of their bodies the way that we would want them to, that a lot of what the doctor ends up doing is sort of negotiating with the world on behalf of my patients

to get them things I think they need. The other thing I would say is that because my patient population, you know, health is socially determined up to a large degree, so like when you describe, like, you go to the doctor, you say something's wrong with you and they give you a medicine,

you're picturing going for like strep throat or something, right? Yeah. Or I have the flu and I want Tamiflu because that's the experience of people who aren't sick. But my patient population is sick. So they are living with illness all the time. And when they are coming to me, they're not coming necessarily with a new complaint

so much as we are in this constant process of trying to modify their experience of illnesses that they live with chronically. There's nothing about anything you've described where my under-informed stereotypical view of the world you're treating would say, like, this is the pop culture sketch I have been given of OZembe users. Can you tell me the first time you heard about GLP-1s?

Like, when did they show up on your radar? Yes. So, right, exactly. And this is sort of my whole interest in these medicines to a large degree. So GLP-1s have been around for a really long time. Like some version of GLP-1s have been around for almost 20 years. There were sort of like first-generation GLP-1 medications that were only used for diabetics. So I've known about those medicines for a really long.

long time. But the sort of GLP-1's class that is like the OZemic generation and then everything that's followed really came on the radar like 20, 2021, 2022. And I think the first time I sort of started paying attention to them was when

I read about them in mainstream media, not in medical literature. Because, especially like those very early months, like they weren't accessible. Extremely expensive. And so there were sort of these studies that had been done, you know, by Novornoirius, suggesting, like, incredible results for diabetic patients. But there are lots

of medicines of being invented all the time that are really promising, but that are too expensive and are just, like, not going to be on formulary for my patients that I don't actually know that much about. I think the way that I personally got really interested in the GLP ones was I actually think that somebody I know who worked at Vogue called me, called me, and was like, what's the deal? You know, like, everyone I know wants this medicine. Like, what's the deal? This medicine? And I was like the diabetes drug? Like, you know, it was sort of not on my radar. And then I started to be interested in it as the weight loss effects became clear,

well known. And then the drug started to be sought by a patient population that didn't have diabetes, but that wanted to use it for weight loss. And it became sort of this like cultural phenomenon. And like I think 2022, 2020, 23 is really when that happened. Like, 2023 is the year to me of the Ozambic first person essay. Yes. 2022 was the year for me of people whispering about it.

Right. Yeah. And then 2023 was people being like, all right, I did it. I tried it. Or like, or what does it mean for the body positivity movement that this is happening or whatever? Like that, right? It was this really interesting thing where this diabetes medicine became this other thing. And at that point, like really controversial, right?

Yeah. It was a medicine that was also a discourse subject. Right. Exactly. Exactly. And it like scrambled all these. There were so many relatively set battle lines and ideas about. about, as you said, like body positivity.

And then you had this thing, which just, it took this table and just like shook it really, really, really hard. Totally. And it was so unexpected, frankly, right? Because one of the sort of truisms up until this class of medicines was we didn't have a magic pill for weight loss, right? That there had been sort of all of these prior cultural moments like Fen-Fen in the 90s, where there had been like a hot discourse object medicine to help people magically shed pounds. Nothing prior to GLP-1s had been proven safe in a way that it could be sort of a sustained intervention for people. Nothing really worked that well.

Whereas, like, all of a sudden, people were taking OZUMPIC. It seemed safe. They were tolerating it okay, and they were losing 15 pounds in five weeks. And that it was just so unprecedented in its efficacy. Like, we hadn't had anything like that before. I mean, like these drugs, by the end of 2023, we knew that they had an all-cause mortality benefit. Like, that's unbelievable as an outcome. There are very few things in medicine

where you can show that it prevents people from dying over a very short period of time of taking the drug. And this did that. And so, like, it was really an incredible, from a medical perspective, it was super exciting. And at the same time, there was this, like, weight loss, body image, yada, yada, discourse that was totally divorced from the actual medical impacts

of the drugs. This yada yada discourse Dr. Bedard's referring to, that's what I was referencing in the beginning of this episode. A season which yielded many essays from writers wondering out loud if these new drugs were just morally wrong. To Dr. Bedard, the problem with these pieces is that they rarely seriously engaged with a world beyond the writer, their social circle, and celebrities on Instagram.

I was annoyed on a bunch of different levels. One thing is that it just highlighted how much cultural, discourse about bodies, even illness, medicine, people's experience of their bodies really almost never reflects the experience of people who are actually ill. So, you know, type 2 diabetes is like one of the most common chronic conditions that Americans live with. It's really, can be really terrible, right? Like, millions of people in this country have had a limb amputated because their diabetes was sufficiently bad that they had vascular complications where they stopped getting blood flow to a limb, and they had to lose a leg, you know, that's really terrible. There are half a million people

in the U.S. who are on dialysis, which means that three times a week, they go for several hours and sit in a recliner, in a room full of people in recliners, hooked up to huge IV catheters that are exchanging their blood through this, like, blood washing machine, dialysis machine. that's a wild way to live, right? Imagine if you had to do that. And those experiences are never reflected in first person writing about illness in the mainstream media. They're almost never actually described, I think, in, you know, the publications that, like, I read both for news and pleasure. Whereas I'm 43, I think for as long as I can remember, I have been reading an essay a week about.

what is like to be a white lady who doesn't feel great about her weight. That is a constant in my life through many changes in the world. And the idea that this breakthrough class of medications that had the potential to revolutionize, like, chronic disease, population health in the U.S., potentially changed the expected mortality for Americans, like that it was all sort of being funneled into this same discourse and also processed using the same types of anxieties and neuroses that were sort of the themes that I've been reading about my whole life.

Yeah. It was really annoying to me. To Dr. Bedard, what was annoying in 2023 was how the conversation about these drugs gave almost all of its oxygen to their cosmetic attributes. What did it mean for everybody's body image, that thinness was now much easier to buy than it had been before? I can feel even now saying that sentence,

the heat and excitement of all the arguments it provokes. But for Dr. Bedard, those arguments made her want to yell at the screen. Forget even for a second the cosmetic implications. GLP-1s were transforming the lives of some of her most vulnerable patients. She thought more of the oxygen in the conversation should have gone there, and that the discourse certainly should not have been so focused on the very particular lives of media elites. we're going to take a short break. When we come back, we're going to move away from discourse,

away from the conversations of yesterday's internet, to today, the actual science behind GLP-1s, and all the weird things doctors have been learning about them in their last three years of widespread deployment. This episode of Search Engine is brought to you in part by Vanguard. To all the financial advisors out there whose job is to help your clients keep more of what they earn, Vanguard is here to help you with that.

Vanguard is slashing fees again. this time for more than 50 of its funds. That's on top of big fee cuts they gave last year to investors in 87 of their funds. In an increasingly high-priced world, Vanguard is staying true to excellence without expense. With Vanguard, your clients get access to sophisticated, active, and index bond funds at industry-leading low costs, backed by a fixed-income team that's truly obsessed with consistent outperformance. Lower fees don't just mean savings. They give Vanguard's skilled bond managers more freedom to maneuver as they pursue strong results.

and they give you more flexibility to deliver measurable value to your clients. Because top performance shouldn't come at higher cost. Go see the record for yourself at vanguard.com slash impact. That's vanguard.com slash impact. All investing is subject to risk, Vanguard Marketing Corporation distributor. This episode of Search Engine is brought to you in part by Instacart. Instacart is more than a grocery technology platform.

It's really about giving you back time and making everyday tasks feel a whole lot easier. It connects you to thousands of stores across the country so you can get what you need without having to plan your whole day around it. Lately, I've been using it a ton when I'm trying to just stay on track with meals during the week. I'll sit down, map out a few recipes, and just build my cart with the things I'll need. Specific ingredients, brands I like, even the little things that I would normally forget. Really feels like everything is being chosen thoughtfully, which makes a huge difference if you care about quality.

Plus, there's the convenience factor, which is what honestly just keeps me coming back, Whether I'm planning ahead or just realizing last minute that I'm out of basics, I can order through the app and get what I need on my schedule. Instacart brings convenience, quality, and ease right to your door so you can focus on what matters most. Download the Instacart app now and get groceries, just how you like. This episode of SearchEgeon is brought to you in part by Gusto. Okay, quick question. Have you ever sat down to just check one payroll thing, and suddenly it's like two hours later

you're buried in forums, Googling tax stuff, and questioning your life choices? Gusto is here to relieve that problem. Gusto is online payroll and benefits software built for small businesses. It's all-in-one, remote-friendly, and incredibly easy to use, so you can pay, hire, on-board, and support your team from anywhere. It handles automatic payroll tax filing, does direct deposits, and even helps with benefits like health insurance and 401ks. Basically, all the stuff that you're used to stressing you out just gets handled.

It's one simple monthly price with unlimited payroll runs, no weird fees popping up. Plus, if you ever get stuck, you can actually talk to certified HR experts, which is lifesaver. Try gusto today at gusto.com slash search and get three months free when you run your first payroll. That's three months of free payroll at gusto.com slash search. One more time, gusto.com slash search. Welcome back to the show. So can you tell me literally just like, what are GLP ones doing inside of your body? Like what are the mechanics of how these drugs work?

Okay, so when we're talking about GLP-1s as a class, we're talking about this class of medications. The first one actually came out in 2005, but this popular conversation is referring to the ones that have come out in the last couple of years. And the sort of first one is semaglutide, which is Ozempic or Wagovi. Then the second one that's already approved and been on the market for a couple years is terseptide, which is Zepbound or Mungaro. And then there's this one in the pipeline that I literally cannot pronounce the one with the R. Red at Trutide. Red at Trutide. It's like the worst possible name. Yes.

Like I can't spell it. I can't say it. So semaglutide is this peptide that is a GLP1 agonist. An agnist means that it's a peptide that binds to the GLP1 receptor in the body. And GLP1 in the body does a couple of different things. It slows gastric emptying, so it makes your stomach stay full long. Like, not the feeling, not just the feeling of being full, but literally, like, if I eat a salad, it stays there. Exactly. That does absolutely increase your fullness and gets you to fullness faster.

Yeah. It also does increase your sense of fullness by working on, like, hormone receptors in the brain. And it decreases hunger and increases satiety. And then it, and this is why it's really important in works in diabetes. It works on glucose balance. And so it provokes the pancreas to release in the, insulin in response to high glucose levels. So it doesn't cause your pancreas to just like willy-nilly release insulin all the time,

but it augments the insulin response to high glucose levels in your body. And what's the relationship between, like, glucose enters my body when I eat like sugar or bread or something like that? What's the relationship between glucose and insulin? So when you eat anything that has carbohydrates in it, it gets broken down to release glucose, which is like sugar, in your blood. in response to glucose in the blood, the pancreas, which is like an organ in the back of your belly, releases insulin, which is a hormone. Insulin helps your muscles take the glucose out of your blood into the muscle and use it for energy. What happens in people of type 2 diabetes or people of pre-diabetes is they develop insulin

resistance, which means that they have decreased response to insulin, which means they are less effective at taking the glucose out of your blood. and that means that your body needs to release more insulin in order to take that glucose out of your blood. Yeah. So for diabetics, who often have very high levels of glucose just like circulating in the blood, high levels of glucose is called hyperglycemia. It has all sorts of downstream effects. It hurts your eyes.

It hurts your kidneys. Eventually, it contributes to plaque buildup in your arteries, which can cause heart attacks and strokes. So what you want to do in diabetics is get their glucose levels, their average circulating glucose levels down. And GLP1 agonists help do that by signaling to your pancreas when you have a glucose spike to release insulin so that the glucose spike doesn't spike too high. Basically, it helps sort of maintain your glucose levels within a range that your body can handle.

And GLP1 agonists through that sort of combination of effects, the semaglutide like Wago-Zemps lead to like 10 to 15% body weight loss over the course of a year. the studies. But the thing that I think is really interesting about these drugs. And one of the reasons that they've inspired so much excitement is because they've had effects that we sort of anticipated that were like targeted effects in the initial trials, improved blood sugar, control, and weight loss. And then they've had a bunch of unexpected downstream effects

probably related to weight loss and better blood sugar control, like they prevent heart attacks, they prevent strokes, they prevent people from progressing to diabetic kidney disease. They seem to improve people's knee arthritis, which like was really unexpected. They seemed to improve heart failure. And then they also have this potential effect around addiction. And that's interesting because you really can't attribute that impact to weight loss. So like, there's no reason to think that if I'm 225 pounds or 180 pounds, I should want to drink more or less. Right, exactly. Other than maybe there's some psychological impact, et cetera, et cetera.

But what we're sort of interested in is it's revealed that there are GLP1 receptors in places where I think we didn't totally recognize they were there, didn't fully recognize their potential role in things that we weren't thinking about. So there are GLP1 receptors in like the dopamine reward circuitry in your brain. brain. And one sort of hypothesis around the addiction stuff or the sort of strongest hypothesis is that GLP1 agonist binding there is interrupting reward circuitry pathway stuff in a way that for people who have strong reward pathways built around addictive behaviors, like it interrupts that. And is it like these sort of unexpected positive effects,

the ones that are sort of surplus effects that go beyond what you would have modeled as likely benefits of just, like, losing weight. Does it suggest that maybe being, like, a certain amount of overweight can be more dangerous to our health than we understood? Or is it more like these things are just doing things in places that we don't understand? I think it's the first. I think that one of the things that's really interesting about the diverse array of effects that the GLP1 drug seem to have is that it's suggested of the fact that obesity,

and what people who study obesity have long asserted is a pathological condition that has consequences way beyond just being overweight and moving around the world in a bigger body. Having a lot of excess fat tissue on your body changes all sorts of hormone signaling and homeostasis mechanisms in your body.

So losing that adipose tissue, that fat tissue, makes a huge difference in changing how your body self-regulates. And that seems to be. to improve a whole bunch of things that we maybe didn't totally anticipate. There's this sort of hand-wavy thing that the GLP ones decrease inflammation,

which is true. We sort of do know that, that they decrease inflammatory markers in the body. And just seeing all the different ways in which decreasing inflammation seems to help people is really fascinating. Yeah.

You've described the known benefits. You described that there's some, like, I don't want to say unknown possible benefits, but like question-marking things that look good. A million things that are like question-marky things that look good. Like I should just list some of them because it's so exciting. Cancer prevention.

So we know this is another one where like on the one hand we know that there are a bunch of cancers for which obesity is a risk factor. Breast cancer is like that. colon cancer is like that. GLP1 seem to help with those. There are a bunch of cancers where we don't think

of obesity as being a risk factor. Where GLP 1 is because of this anti-inflammatory sort of of impact, we're not totally sure, may also play a role. So there are trials to look at cancer prevention. There are trials to look at Alzheimer's prevention. The first Alzheimer's prevention trial was negative, which means like the drug didn't make a difference, but I don't think it's conclusively negative that it doesn't help with Alzheimer's prevention or treatment necessarily. There's more trials to be done there. There are trials happening in Parkinson's disease. Like,

these are big, extremely common conditions that either lead to death or that totally. derail people's lives. And so the potential benefits that are still undercharacterized or unproven are super exciting. And what are the current unknown or questionable possible harms that you're tracking? I mean, one that's sort of been studied some, but I think not in a way that's super, super conclusive is for some people it does seem to provoke a depression. There's been this concern about increased suicidality that has not borne out in studies thus far, but like it's on the radar is a thing that people are concerned about. But these psychiatric neurologic complications I'm interested in and paying attention to, the most common side effects with these drugs are the

GI side effects, so like bad nausea and vomiting and constipation. And so I'm really interested in both increased clarity around what standard of care looks like for prescribing them to minimize those side effects, and whether these future, like, GLP1, 2.0,0, 3.04.0s are going to improve that side effect profile, because that would actually make a very big difference. Right, because there's people that can't tolerate their side effects. Yeah, I mean, some people are really nauseous and vomit at the beginning because they just haven't figured out how to eat on the drugs, like they're still eating too much. But some people have, like, constipation that they just can't tolerate.

Some people are persistently nauseous in a way that doesn't get better for most people. it gets better. But that's a real, like, rate limiting step. So there's a world of discourse and media, which I belong to, which bungled this story for at least a year. In the world of the patient populations who you treat, like, what was actually happening far away from the discourse? Can you just tell me stories, like, from early on, like, what type of patient was taking these medicines at your clinic and how is it affecting them? Sure. So I work in New York City. New York State has generous Medicaid. New York City's public hospital system has its own pharmacies, and they did some amazing job I don't totally understand in which they were able to provide access to the GLP ones, even during the period. It was very, very hard to get them at sort of regular community pharmacies. And so between both that sort of generous insurance and that action, access in our hospital pharmacy, I have had this incredible good fortune of being able to prescribe OZMPIC for diabetic patients since like 2023 or 24 who are poor and otherwise would not have

access to it, right? And this is like a huge issue, is that, like, for most patients like my patient population, they aren't on it yet because their insurance doesn't cover it. Yeah. Or if their insurance covers it, it covers it only for a very narrow set of indications. And they have trouble getting it or whatever it is. My patients have been able to get it the whole time. And I do think it's sort of like a miracle breakthrough in primary care for underserved populations that have the morbidity burden that my patients have. So most of my patients have diabetes and high blood pressure and high cholesterol and some

degree of kidney disease and maybe some degree of other complications of diabetes like retinal disease in their eyes and fatty liver disease. Most of my patients also have some addiction history in my homeless clinic, so alcohol or other substances. And it's been my experience that for the patients for whom I've been able to prescribe OZembek, which is the one that I've been able to get paid for, it really does help with all of those things. Like their diabetes improves, they lose weight, their chronic pain improves, their blood pressure improves, their cholesterol markers improve. and patients really like it. I mean, what did they say?

Like, I had this great paranoid schizophrenic lady who was on it. She was the first patient I ever prescribed it to in primary care. And she was in my office, and she's sort of like a little bit psychotic at baseline. But she takes her medicines. So she's telling me some story, like, I kind of can't follow about like some people who have been, like, tapping her phone. And then I said, oh, wow. You lost like 12 pounds or something because I'm looking at her chart. And she paused and she like locks in and she goes,

I haven't weighed this much since 1996. And I died. Like I was like, you go, girl? Like amazing. So happy for you. And that's like, that's been true for a bunch of my patients that they feel better in their bodies both psychologically and physically. And they don't work for everybody.

There are certainly, you know, five to 10 percent of people who don't tolerate them because the side effects are too much. Like some people just get much more nauseous than the average person. And then they're just like, I can't do this. I don't like it. A few people have said more in my personal life than my practice that they thought that they felt low on them, that made them feel a little bit depressed. I haven't had that happen in my practice.

But, you know, that's just to say that there are a bunch of reasons why some people don't tolerate them. But for people who tolerate them and for whom they work, they're an incredible intervention. Most of my patients are on like eight to ten medicines a day. and for them to be able to take one shot a week, lose weight, improve their diabetes, improve their high blood pressure, improve their high cholesterol, you know, carrying less weight and also have less inflammation in their body so their pain is better, their depression is better. Like, that's an extraordinary thing to be able to offer them. It's not everybody's experience, but for people, for whom it worked, like, it works better

than any other single intervention I've ever given someone other than curative ones. And so, like, I'm unbelievably grateful for them, and I'm incredibly excited about them. You know, like, I think as there's this arms race in developing better, more effective, more targeted GLP-1s, and as we get more and more studies about how to dose them correctly for different conditions, et cetera, et cetera, like, you know, I mean, it already has, but it will absolutely revolutionize primary care practice. Dr. Bedard says that part of this revolution has come because maybe surprisingly, maybe not, one side effect of the huge. huge demand surge for these drugs in 2023 and 2024, is that the price has been driven down.

When the manufacturers of drugs like Ozempic couldn't meet demand, compounding pharmacies entered the marketplace, selling compounded versions at a much lower price. That ended up pushing prices further down, even on the name brand GLP ones. So now semi-glutide, which not so long ago

cost $1,200 a month without insurance, can be found online for as low as $150 a month. A health care market that, for once, seems to have kind of sort of worked eventually. We're going to take one more break, and when we come back, Dr. Bedard gives us her take

on people who are taking these shrugs for decidedly off-label use. Owning a home is full of surprises. Some wonderful, some? Not so much. And when something breaks, it can feel like the whole day unravels. That's why homeserv exists. For as little as $4.99 a month,

you'll always have someone to call, a trusted professional ready to help, Bringing peace of mind to 4.5 million homeowners nationwide. For plans starting at just 499 a month, go to homeserve.com. That's homeserv.com. Not available everywhere. Most plans range between 499 to 1199 a month your first year. Terms apply on covered repairs.

Ambition comes in all shapes and sizes. At First Citizens Bank, we roll with your goals because we're built for what you're building. Fit for your ambition for Citizens Bank. So good, so good, so good. Springstiles are at Nordstrom Rack stores now, and they're up to 60% off. Stock up and save on Rag and Bone made well. Vince, All Saints, and more of your favorites.

How did I not know Rack has Adidas? Why do we rock? For the hottest deal. Just so many good brands. Join the Norty Club to unlock exclusive discounts, shop new arrivals first, and more. Plus, buy online and pick up at your favorite rack store for free. Great brands, great prices. That's why you rack.

Welcome back to the show. Do you, just in your social life, do you have like non-patient people, like friends, family members still asking about the drugs? Constantly. Constantly. Constantly. Like, I take like an unofficial as I'm like a consult a day. What do you tell people right now? I mean, I am very GLP1 supportive.

So, you know, it's case to case. Like, it's not for everybody. But I will give you sort of examples of like the kinds of things. Like, you know, I have lots of women in my life who are struggling. with postpartum weight gain, or like pregnancy weight gain and not being a postpartum feeling overweight. Or people who, one of their real anxieties about getting pregnant again, is that they gained a huge amount of weight and they don't feel like they're back in their own bodies and they don't want to gain more. I'm really supportive of people using a GLP1

for a period of time to help them lose, you know, weight that they gained really suddenly and are having a hard time losing. There are obviously some people who have long histories of eating disorders in their lives, right? And where you think, I think if you do this, this is not going to be great for you, actually. Like, I think that this is reigniting a series of obsessions that, like, you've done a lot of work to try to get past.

For those folks, I don't think that they should, you know, entertain the idea of a GLP one. But for lots of people, I think it's a fine thing to do. Do you talk to people who are talking about using it, I guess, awfully able to manage addictions? I have, so I know one guy. who was taking it so that he would post on Twitter less. Really?

Yeah. Did it work? He said so. And then he's posting a lot recently, so maybe he's off. I don't know. If I really thought it was a cure for Twitter use, there's people, I would stand outside other people's houses with like a blow gun. I mean, you know, I think, yes, I'd absolutely have people who, I have a close friend

who's primary motivation in trying it was that he wanted to drink less. he also probably wanted to lose 10 or 15 pounds, but probably wouldn't have taken it just for that alone. Yeah. Asked, and I said, yeah, try it, see how you tolerate. You know, the other thing is that they just are quite safe. That doesn't mean that they're safe for everybody to take for 60 years week after week. You know, like we don't totally have exactly that data,

but we have 20 years of data about this class of medicines, and we have a pretty good sense of there is a very narrow slice of the population who they're totally inappropriate for if you've had a family history of certain rare cancers for the majority of people, giving them a shot and seeing how you tolerate is totally appropriate and fine. And so this friend took them, he didn't identify as an alcoholic,

but he identified someone who wanted to drink less and who drank daily. And for this friend, he took them for six months or something or four months, totally changed his relationship to drinking. I think he's been off now for a little while, and he said he's,

not back to drinking the way that he was. He feels, that relationship feels altered for him, even if he's not as suppressed in his desire as he maybe was when he was, like, on the medicine week after week. I had one last question for Dr. Bedard. I wanted to know if she had a perspective on a class of drugs that are adjacent to, but in my view, fairly different from GLP-1s, internet peptides, the wilder west of molecules

many people are now using, drugs we've covered elsewhere on the show. I think that I think that it is both GLP-1s and peptides to some degree are part of a larger shift in health, wellness, medicine, which is this paradigm shift between thinking of medicines as things that we use to treat illness, to thinking of pharmaceutical products as something that we offer people to help them feel the way they want to feel. Is that a bad shift? Is that a neutral shift? It's a complicated shift, I think. So, you know, the better example to me than peptides is like the use of hormone supplementation for a million different indications, right? Like that's another huge discourse.

It's like, you know, women taking estrogen supplementation in their early 40s when they start to feel what they self-diagnosis, parimenopausal symptoms, women on testosterone. There's been a bunch of essays about that. men on test, you know, like, it's a very different way of conceptualizing the rule of health care than it's not why I went into health care, and it's also different from the sort of paradigm I trained in. But I'm also just a little bit trying to remain neutral about this in thinking about the changing relationship between patients and providers to one that's a more sort of shared goal-setting, shared decision-making model, which doesn't quite answer your peptide's question, but I kind of see all of the peptides, the GLP-1s, the cosmetic procedure stuff.

It's like all part of a thing of like I don't feel the way I want to feel in my body. I don't look the way that I want to look in my body, et cetera, et cetera. I'm going to seek medical intervention to help me become the thing that I want to become. I have really complicated reactions to it, but I don't yet have a definitive opinion about I'm really trying to think it through. I can't tell if what you're describing is that interventions that we just would have understood it as cosmetic before, are becoming much more socially acceptable, or if it's more complicated, which is that like interventions like we thought of as cosmetic, we're now in our own minds labeling

as medical. I think it's the second one. So I think that we have, in a weird way, medicalized a lot of the experience of being, like, in the human life cycle, you know? And that's complicated. You know, and again, like, these are all sort of questions and discourse topics, et cetera, are they're so far afield from my medical practice and my patient's lives and my patient's bodies. And they're so far afield from sort of what are the things that sick people actually live with, what are the things that actually kill people, et cetera, et cetera. So with this sort of large caveat that all of my initial anxieties about the GLP1 discourse apply to this other sort of wider discourse around other interventions that are for self-fulfillment

but are sort of being medicalized, I'm trying to be like a little bit. thoughtful before I just sort of react to them as a knee-jerk moral panic around those. But it's like you feel uneasy, but you feel uncertain about your uneasiness. Yeah, I'm like really working through it. I think that's an intellectually honest position. Thank you. Thank you for talking about this. My pleasure.

Thank you for having me. Dr. Rachel Bedard, she's doctor and writer, will have a link to her story about the rise of Oz epic in the show notes. Also, I have to say, there was one more part of this conversation which It was the part I found myself talking the most about with friends this week afterwards, but it was on a slightly adjacent topic. So we got more into this idea of cause medicine, like the place where cosmetic interventions and medical interventions kind of meld together

and about how there are middle-aged people who are thinking about interventions like taking testosterone or estrogen or going to the dermatologist for lasers to try to look more the way they think and Hathaway looks, or men going to Turkey to get a new hairline. I don't know how we're supposed to think about this era where looking older seems to be becoming more optional, where many people on the internet seem forever 35. And talking to Dr. Bedard, who is also working this stuff out, it really helped me. These ideas have already been swirling around my brain. It's settled them a little bit. If you want to hear that conversation, we're going to publish it as an extra small feature on incognito mode. You can sign up for that at search engine.com.

If you're already signed up, it is in your feed now. Search Engine is a presentation of Odyssey. It was created by me, PJ Vote, and Truthy Pinnaminani. Garrett Graham is our senior producer. Emily Malt-Tahara is our associate producer. Theme, original composition, and mixing by Armand Bizarrian. Our production intern is Piper Dumont. Piper also fact-checked this episode.

Our executive producer is Leah Reese Dennis. Thanks to the rest of the team at Odyssey, Rob Morandi, Craig Cox, Eric Donnelly, Colin, Gainer, Moore, Kuren, Josephina, and Courtney, and Hillary Schaff. Also, if you have a business, which you would like to average on our show, please email us. Email address is PJVote85 at gmail.com, subject line,

advertising. If you'd like to support our show, get ad-free episodes, zero reruns, and bonus audio, including this week. Please consider signing up for Incognito mode at search engine.com. Thanks for listening. We'll see you next week. Wireless can feel like a world of traps,

but not with visible. It's one-line wireless with unlimited data and hotspot, powered by Verizon for $25 a month. taxes and fees included. Plus, for a limited time, new members pay just $20 a month for one year on the Visible plan. Using the code Fresh Start. Refresh your wireless with Visible.

Tap the banner to switch today. Terms apply, limited time offer subject to change. See Visible.com for plan features and network management details.